2021 where science meets art. annual report

1 2021. where science meets art. annual report 2021 annual report . DearShareholders, Our past scal year, ending June 30, 2021, was extraordinary, for both society and for our organization. During this unprecedented time, we made substantial progress across key areas of our business, including enlarging our infrastructure, growing our talent, deepening our long-standing commitment to sustainability practices, and accelerating our growth strategy, all while delivering record nancial results. In response to the global COVID-19 pandemic, we scaled our capacity to meet demand for vaccines and treatments.

2 At the same time, we continued to develop and manufacture a broad range of other important medicines and consumer products to address the needs of millions of patients and consumers. None of this would have been possible without our more than 17,000 team members, whose dedication allowed us to advance the company, elevate our brand within the biopharma industry, and deliver for customers and patients during this tumultuous period. The pandemic showcased the depth and breadth of our capabilities and highlighted our important role in the healthcare system.

3 As we look ahead, we will use our greater knowledge, new capabilities, and strengthened partnerships to accelerate our mission to develop and deliver products that ultimately allow people to live better, healthier lives. FISCAL 2021 IN REVIEW. COVID-19 Response: Meeting the Needs of Customers and Patients Worldwide While Keeping Our Employees Safe uniquely positioned at the onset of the pandemic to support the biopharmaceutical industry in developing and manufacturing COVID-19 vaccines and therapies. As the scope of the pandemic became apparent, we accelerated additional investments in our capacity, including: The launch of two dedicated vial lling lines in Bloomington, Indiana.

4 The rapid scale-up of our drug product capabilities in Anagni, Italy;. Increased viral vector manufacturing capacity in Harmans, Maryland; and Two new suites at our biologics drug substance development and manufacturing facility in Madison, Wisconsin. Since the start of the pandemic, we've been awarded work on approximately 100 unique potential COVID-19. vaccines and therapies. Our unique position enabled us to make hundreds of millions of COVID-19 vaccine doses since December 2020, and we now have the manufacturing capability and capacity to produce billions of COVID-19 vaccine doses over the next few years, including more than one billion vaccine doses in calendar year 2021.

5 In addition to meeting the demands of customers and patients, our top priority throughout the pandemic has been to keep our people safe. We are proud that the comprehensive safety protocols we implemented, combined with the persistence, dedication, and exibility of our employees, enabled us to avoid any signi cant business disruption. And we are equally proud of the new measures we put in place to support our employees during the pandemic, including exible work where possible, implementing COVID-19 sick pay, and investing in mental health and family-support initiatives.

6 We also issued thank you bonuses to our frontline employees, which have totaled more than $20 million since the beginning of the pandemic. These actions showed us new ways of working and supporting our people that will continue beyond the eventual end of the pandemic. 2021 annual report . Investing in Growth 29% as reported, or 26% in constant currency, In scal 2020, we dedicated signi cant resources compared to scal 2020, of which 25% was toward continued, long-term organic growth. Adjusted EBITDA was $ billion for scal 2021, Speci cally, we signi cantly expanded our global representing constant-currency, organic growth of drug product capacity, completed the build out 32%, compared to scal 2020.

7 2 Adjusted Net Income of ten suites at our gene therapy commercial per diluted share was $ , compared to $ manufacturing campus and began construction in scal 2020. 3 We also further strengthened our of ve additional suites, advanced our European balance sheet in scal 2021 as we took advantage commercial buildout in cell therapy, invested of the favorable lending environment to re nance in cryogenic capabilities for clinical supplies a substantial portion of our long-term debt and services, and worked toward the future launch meaningfully reduce our weighted average interest of our unique Zydis Ultra dosage form.

8 Rate below 3%, while also pushing out our nearest maturity to 2027. We ended the year with $967. In total, our capital investments, which were million of cash, cash equivalents, and marketable principally directed to organic growth projects securities, and our net leverage ratio at June 30, 2021. in our Biologics segment, totaled $686 million in was , providing Catalent with the exibility to scal 2021, a record level for the company and a continue to make organic or inorganic investments 47% increase over the scal 2020 total of $466 intended to further propel our long-term growth.

9 Million. We expect to continue our current pace of organic growth investments in scal 2022, Corporate Responsibility which include the rst phase of a planned $100 Enhancing our environmental, social, and corporate million expansion program to add biologics drug governance (ESG) frameworks and metrics has substance manufacturing capabilities in Europe. been an important objective for the company, and I am extremely proud of the progress that In addition to organic investments, we also Catalent has made over the last several years. continued to acquire companies and other assets Our approach prioritizes our impact on people, to build platforms for future growth.

10 Acquisitions the environment, and our communities. Our in scal 2021 totaled $147 million and included Corporate Responsibility Council guides the adding capabilities and capacity in plasmid DNA implementation of our strategy and has begun manufacturing, cell therapy manufacturing, delivering regular reports to our board of directors. and dry powder inhaled dose forms. In May, we published our second annual Corporate And in August 2021, we agreed to purchase Responsibility report , which tracked our progress Bettera, a major manufacturer in the high-growth against ESG metrics that align with the standards set gummy, soft chew, and lozenge segments of the by the Sustainability Accounting Standards Board nutritional supplements market, for $1 billion.